News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
MacuSight, Inc. Raises $8 Million, Bringing Total Series A To $25.5 Million
September 27, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MacuSight Inc., a developer of therapeutics for severe ocular diseases and conditions, has secured $8 million in Series A funding from its investors to further clinical trials for its main ocular disease treatments.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
Obesity
Lilly’s Weight Loss Trio Could Top $100B in Revenue Thanks to Oral Option
November 19, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
November 19, 2025
·
3 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
Genmab Prunes Another ADC From $1.8B ProfoundBio Acquisition
November 18, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Nxera’s Quest for Profitability Claims 15% of Workforce
November 18, 2025
·
2 min read
·
Tristan Manalac
